

Industry Experience on Collection of Data on Volume of Antimicrobials and Proposals for the Future

HMA Stakeholder Meeting Mariánské Lázně 20 May 2009

Dr. Ludwig Klostermann
IFAH Europe





- Experience with AB Survey of CEESA
- Challenges and Outcome
- Key Learnings
- Conclusions
- Key Elements for Consideration and Proposals

Experience with CEESA AB Survey



- Project initiated in 2005
- Collection of data in kg active substances
- 2002 2004 2006
- Under CEESA* umbrella
- Alpharma, Bayer, Ceva, Elanco, Fort Dodge, Intervet, Merial, Novartis, Pfizer, Schering-Plough, Vetoquinol, Virbac
- "Central" data generation approach

*CEESA = European Animal Health Study Center; a Brussels based non profit association

Challenges and Outcome



- Competition laws
- Companies financial systems only partly suitable
- Changes in systems over time
- Company mergers
- Local versus core products

Key Learnings



- Central data collection difficult
- 2002 collection had to be given up
- Validation of data often tbd locally (country level)
- Data do not always match with governmental surveys
- Amounts of generic marketers missing
- Differentiation into species almost impossible
- Competition laws / confidentiality issues for reporting

Industry Conclusions



- CEESA project discontinued
- Industry project on "Collection guidelines" initiated
- Dialog essential
 - Industry / Regulators
 - between Regulators

Key Elements for Consideration and Proposals



- All marketers to be involved!
- National approaches! may be the only way - versus central data generation
- Collection of context data! (e.g. animal production numbers, disease prevalence)
- Simple and pragmatic systems required
- Same or similar collection systems in all Member States
- Discussion on unsolved species differentiation
- Consultation with stakeholders on interpretation of data
- Joint effort industry / regulators essential



IFAH Europe

is committed to an fruitful dialog and cooperation in the interest of all stakeholders